Patents by Inventor Russell Cink

Russell Cink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
    Publication number: 20080051411
    Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
    Type: Application
    Filed: August 17, 2007
    Publication date: February 28, 2008
    Inventors: Russell Cink, Joseph Paterson, Yi Gao, Geoff Zhang, Michelle Long, John Morris, Joerg Rosenberg
  • Novel glucocorticoid receptor ligands for the treatment of metabolic disorders
    Publication number: 20070027117
    Abstract: This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and/or decreasing body weight.
    Type: Application
    Filed: July 21, 2006
    Publication date: February 1, 2007
    Inventors: Richard Bishop, Russell Cink, Bradley Gates, Lars Hagberg, Peer Jacobsen, Philip Kym, Chunqiu Lai, Marvin Leanna, James Link, Steven Richards, Noah Tu, Tom von Geldern
  • Salts of fenofibric acid and pharmaceutical formulations thereof
    Publication number: 20050148594
    Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
    Type: Application
    Filed: June 30, 2004
    Publication date: July 7, 2005
    Inventors: Russell Cink, Joseph Paterson, Yi Gao, Geoff Zhang, Michelle Long, John Morris, Joerg Rosenberg
  • Phorboxazole derivatives for treating cancer
    Publication number: 20050119322
    Abstract: Synthetic Phorboxazole A and derivatives thereof for the treatment of cancer, including inhibition of cancer cell growth, induction of apoptosis, and inhibition of metastises.
    Type: Application
    Filed: September 28, 2004
    Publication date: June 2, 2005
    Applicants: Parker Hughes Institute, Regents of the University of Minnesota
    Inventors: Fatih Uckun, Rama Narla, Craig Forsyth, Chi Lee, Feryan Ahmed, Russell Cink
  • Anti-infective agents
    Publication number: 20050107364
    Abstract: Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
    Type: Application
    Filed: August 24, 2004
    Publication date: May 19, 2005
    Inventors: Douglas Hutchinson, John Bellettini, David Betebenner, Richard Bishop, Thomas Borchardt, Todd Bosse, Russell Cink, Charles Flentge, Bradley Gates, Brian Green, Mira Hinman, Peggy Huang, Larry Klein, Allan Krueger, Daniel Larson, M. Leanna, Dachun Liu, Darold Madigan, Keith McDaniel, John Randolph, Todd Rockway, Teresa Rosenberg, Kent Stewart, Vincent Stoll, Rolf Wagner, Ming Yeung
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Publication number: 20050043351
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1—X5, R5—R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Application
    Filed: June 9, 2004
    Publication date: February 24, 2005
    Inventors: Arthur Gomtsyan, Erol Bayburt, Chih-Hung Lee, John Koenig, Robert Schmidt, Kirill Lukin, Margaret Hsu, Marvin Leanna, Russell Cink, Gilles Chambournier